SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant volatility following an announcement of a massive equity offering intended to finance a substantial backlog of AI-related orders. The community remains deeply divided, with some investors viewing the dilution as a necessary step to scale production for rapid growth, while many others are sounding alarms over the company's financial health, management's history of controversy, and the potential for further share price suppression.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently experiencing significant market volatility as investors recalibrate their positions ahead of the high-profile SpaceX IPO. While the community remains deeply divided between long-term believers in Rocket Lab's launch execution and skeptics who are rotating capital into the larger industry debut, discourse is heavily focused on whether current pullbacks represent a strategic buying opportunity or a broader sector-wide valuation correction.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing significant downward pressure as investors react negatively to the company's planned $40 billion financing and massive capital expenditure surge, despite a strong earnings beat and record-breaking revenue backlog. While long-term bulls remain optimistic about Oracle's AI infrastructure demand and backlog growth, the community is currently debating whether this is a temporary volatility event or a sustained structural concern over dilution and debt leverage.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is experiencing intense volatility driven by conflicting signals surrounding U.S.-Iran military tensions, with traders weighing claims of imminent peace deals against reports of ongoing strikes. Community sentiment is deeply polarized, as investors navigate broader concerns over inflation and the upcoming SpaceX IPO while debating whether current market movements are a genuine recovery or a temporary liquidity trap.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

The SMCX ETF is experiencing intense community focus following a sharp, high-volume price decline triggered by an investigation into alleged export violations and chip diversion to China involving Super Micro Computer executives. While some investors are viewing the volatility as a potential bottom-fishing opportunity and speculating on a short squeeze, many in the community are warning about the inherent risks of leveraged decay, the potential for further reverse splits, and the uncertainty surrounding the underlying company's legal and compliance troubles.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is facing intense market scrutiny as investors react to escalating geopolitical tensions in the Middle East and a contentious economic climate. Community members are actively debating the company's financial future while expressing significant polarization over executive commentary regarding inflation and ongoing military conflicts.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is experiencing a sharp pullback following an earnings report that showed wider-than-expected losses, despite ongoing community enthusiasm for the stock's long-term potential as a U.S.-based uranium producer. Investors are actively debating whether to accumulate shares during this volatility to capitalize on the secular bull case for nuclear energy and domestic fuel independence, or to remain on the sidelines due to current operational costs.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is facing intense scrutiny from investors who are deeply divided over the company's aggressive pivot into the alcohol sector and ongoing share dilution. While some maintain hope for growth tied to upcoming federal regulatory hearings and international medical expansion, the community is vocally calling for leadership changes, frequently citing frustration with the stock's persistent downward trend compared to US-based competitors.

PolySwarm

PolySwarm is currently attracting significant community attention as a low-float, cybersecurity-focused utility token with investors closely watching for potential breakout momentum. Many participants are actively discussing the token's long-term potential, citing its unique AI-driven threat detection utility and historically volatile pump cycles as reasons for continued accumulation during periods of consolidation.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing significant momentum and investor optimism as the company transitions into a commercial-stage powerhouse, with discussions centering on the upcoming J-Code activation for Yartemlea and the potential for a transformative buyout. The community is focused on the strong commercial rollout, pending EMA regulatory decisions, and the strategic value of the Zaltenibart partnership with Novo Nordisk as key catalysts for sustained long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026...

Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus

NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.

PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.

Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down

ZTS misses on Q1 earnings and cuts its 2026 revenue outlook as weaker U.S. companion animal sales pressured results, sending shares down in pre-market trading.

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.

Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised

MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

ANABAnaptysBio Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANAB News